October 23, 2006 -- Connetics accepted a $17.50 buyout offer from privately held Stiefel Labs; after the closing bell, Amgen reported strong earnings/revenues for Q3; AstraZeneca won approval for Seroquel to treat bipolar disorder; the FDA approved Betaseron from Schering for early stage multiple sclerosis; Acadia will spin out Abbey Pharma, which will focus on substance abuse; Zelnorm, a Novartis drug that treats constipation, is also effective for dysmotility-type dyspepsia; Abbott released positive data on Humira for Crohn’s disease; Schering-Plough won FDA approval of Noxafil as a treatment for candidiasis; Vivus discussed positive results on obesity drug Onexa; Somaxon released positive data from a Phase III study of Silenor, a therapy for insomnia; and Replidyne and Forest Labs received a not approvable letter for their community antibiotic. The Centient Biotech 200™ was down almost a point at 3961, a loss of .02%. More details...
